Exhibit 99.1

DCCR in Prader-Willi Syndrome

(Summary of Presentation at FPWR 2016)

Introduction: Prader–Willi syndrome afflicts about 1:15,000 to 1:25,000 individuals, with the US PWS population estimated between 12,500 and 21,000. There may be as many as 350,000 PWS patients globally. Clinical features of PWS include poor feeding in infancy. Hypotonia and low lean body mass are present throughout life. Obesity typically begins around age 2 if the diet is not restricted. Ultimately, the central neurological defect of the disease causes PWS patients to sense that they are starving and signals them to significantly increase their caloric intake. This results in hyperphagia which persists for the rest of their life. Mental retardation, growth hormone deficiency, behavioral problems including aggressive, threatening and destructive behaviors, and neuroendocrine abnormalities are also characteristic of PWS. The death rate among PWS patients is 2 to 3 times that of the general population at all ages, with an average age at mortality of 29. The highest priority unmet needs in PWS as identified by parents and caregivers in a large international survey include: (1) reducing hyperphagia and improving behavior around food; (2) reducing body fat and increasing muscle mass with the potential for improved stamina and activity; and (3) reducing the temper outburst frequency and severity.

Diazoxide Choline Controlled-Release Tablet (DCCR) is a once-a-day tablet of the choline salt of diazoxide. Prior to being tested in PWS, DCCR was evaluated in 7 clinical trials in subjects with obesity and hypertriglyceridemia. Its mechanism of action in PWS is attributable to the effects of agonizing the K_ATP channel in multiple tissues.

Study Design and Patient Population: Clinical trial PC025 was a Phase II study evaluating the safety and preliminary efficacy of DCCR in patients with PWS. The trial utilized a randomized withdrawal design, was conducted at the University of California, Irvine and enrolled 13 adolescent and adult, male and female, overweight and obese genetically confirmed PWS patients. Subjects enrolled in the study were dose escalated on DCCR and then treated with a stable dose through 10 weeks of open-label treatment. Subjects then entered a four week double-blind, placebo-controlled phase where they were randomized either to remain on the DCCR dose they finished the open label-treatment phase at or its placebo equivalent, in which case they were withdrawn from the drug. A subset of subjects completed an additional six months of treatment with DCCR.

Hyperphagia, as is typical for studies in PWS, was evaluated using a questionnaire posed to the parent or caregiver using a recently developed version of the Dykens questionnaire. Body composition was evaluated using DEXA, which was run at the beginning and end of the open-label phase. Behaviors were assessed at the beginning and end of the open-label phase using a questionnaire developed for the PWS Natural History Study, evaluating 23 behaviors grouped into 4 categories. Other endpoints were measured by standard means.

Statistical Methods: Endpoints measured during the open-label phase were analyzed by paired t-test. Endpoints measured during the double-blind phase or over the course of both open-label and double-blind phases were analyzed parametrically by ANOVA, non-parametrically by the Mann-Whitney U test, and by arm using paired t-tests. Changes in frequency of subjects displaying categories of behavior were analyzed by Chi-square test.

Patient Population Baseline Characteristics: The majority of subjects were male (61.5%), deletion sub-types (93.3%). The average age of enrolled subjects was 16 years, and ranged from 11.6 to 21.6 years. There were 10 adolescents and 3 adults enrolled in the study. The average BMI was 38.1, with 3 subjects being overweight and the remainder obese based on BMI. The average percent body fat of enrolled subjects was 51.7% ranging from 36.4% to 60.7%. Baseline hyperphagia score averaged 16.3 ranging from 3 to 32. Seven of the enrolled subjects were White Hispanic or Latino; two were Asian and the remaining 4 subjects were non-Hispanic or Latino White. Six subjects were concomitantly treated with growth hormone while 7 were not.

Results: Hyperphagia was reduced by 32% at 10 weeks (p=0.003), the improvement persisting in those treated with DCCR in the double blind phase through more than 3 months of treatment and regressing towards baseline in those switched to placebo (p=0.027, Mann Whitney U and p=0.08, ANOVA). At the highest dose in the study, hyperphagia was reduced more than 42%.

DCCR treatment for 10 weeks also resulted in highly significant and clinically relevant impacts on body fat (-3.8%, p=0.011), lean body mass (5.4%, p=0.001), and the lean body mass/fat mass ratio (9.8%, p=0.002). These improvements were dose dependent. At the highest dose, subjects lost 6.3% of body fat, showed a 9.2% increase in lean body mass, and a 16.6% increase in lean body mass/fat mass ratio (all p£ 0.01). The effects on body composition were independent of and therefore additive to growth hormone. Lipid changes at 10 weeks included triglycerides (-24.2%, p=0.08), total cholesterol (-6.7%, p=0.04), LDL-C (-12.5%, p=0.02), and non-HDL-C (-11%, p=0.01).

When present at baseline, aggressive, threatening and destructive behaviors were reduced by 73% after 10 weeks of treatment with the frequency of subjects displaying this category of behavior dropping from 70% at baseline to 20% at the end of 10 weeks of treatment (p=0.0006).

DCCR was well-tolerated with most adverse events being mild to moderate and resolving while treatment continued. The most common AEs (>20% or 3 patients) were headache, otitis media and upper respiratory infection and represented common medical complications of PWS or known side effects of diazoxide/DCCR. Two patients withdrew from the study during the open label phase, one due to a transition from home care to institutional care and another due to hyperglycemia. There were no new or unexpected safety findings in this study.

Conclusion

DCCR provided broad-ranging therapeutic benefit to PWS patients. It addresses the highest priority unmet needs in the disease (hyperphagia, body fat, lean body mass and aggressive behaviors) while improving cardiovascular risk factors.

***

The foregoing information regarding Essentialis’s Phase II Clinical Study evaluating the efficacy of Diazoxide Choline Controlled-Release Tablet (DCCR), was presented by Essentialis at the Annual Meeting of the Foundation for Prader-Willi Research on October 29, 2016, and has not been independently verified or reviewed by Capnia. Capnia is providing a summary of this presentation (including additional data) solely for informational purposes regarding the business of Capnia and Essentialis following the consummation of the transactions contemplated by the agreement and plan of merger by and among Capnia, Essentialis, Merger Sub (as defined therein), and the Stockholders Representative (as defined therein).

About Capnia

Capnia is a leading provider and developer of innovative healthcare products to be used for the screening, detection and treatment of medical conditions. Capnia’s flagship products are based on its proprietary technologies, which utilize precision metering of gas flow. Capnia currently markets Serenz^® Allergy Relief in the UK. The CoSense^® ETCO Monitor measures ETCO, which can be used to detect hemolysis and the Infant Solutions product line, including innovative pulmonary resuscitation devices for neonates and infants, are marketed globally. Capnia is also clinically evaluating its nasal, non-inhaled CO₂ technology to treat trigeminally-mediated pain conditions such as cluster headache and trigeminal neuralgia. For more information, please visit www.capnia.com.

About Essentialis

Essentialis is a privately-held clinical-stage pharmaceutical company focused on the development of breakthrough medicines for the treatment of rare metabolic diseases where there is increased mortality and risk of cardiovascular and endocrine complications.

Capnia’s Forward-Looking Statements

The foregoing presentation contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ability to complete the merger and initiate the Phase II/III trial in the second half of 2017.

We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this presentation. As a result of these factors, we cannot assure you that the forward-looking statements in this presentation will prove to be accurate. Additional factors that could materially affect actual results can be found in Capnia’s Form 10-Q filed with the Securities and Exchange Commission on November 14, 2016, including under the caption titled “Risk Factors.” Capnia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.